PROGRESSION-FREE SURVIVAL IS A ROBUST SURROGATE ENDPOINT OF OVERALL SURVIVAL IN IMMUNOTHERAPY TRIALS OF HEPATOCELLULAR CARCINOMA

被引：0
|
作者：
Cabibbo, Giuseppe [1 ]
Celsa, Ciro [2 ,3 ]
Enea, Marco [2 ]
Battaglia, Salvatore [2 ]
Rizzo, Giacomo [2 ]
Busacca, Anita [2 ]
Matranga, Domenica [2 ]
Attanasio, Massimo [2 ]
Reig, Maria [4 ]
Craxi, Antonio [5 ]
Camma, Calogero [3 ]
机构：
[1] Univ Palermo, Dipartimento Biomed Med & Interne Specialist Di B, Sez Gastroenterol & Epatol, Palermo, Italy
[2] Univ Palermo, Palermo, Italy
[3] Univ Palermo, Sect Gastroenterol & Hepatol, Dipartimento Promoz Salute Materno Infantile Med, Palermo, Italy
[4] Univ Barcelona, Hosp Clin, Barcelona Clin Liver Canc BCLC Grp, Liver Unit,Idibaps,Ciberehd, Barcelona, Spain
[5] Univ Palermo, Dibimis, Gastroenterolgy & Liver Unit, Palermo, Italy
来源：
HEPATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1068
引用
收藏
页码：649A / 649A
页数：1
相关论文
共 50 条
  • [1] Progression-free survival is a robust surrogate endpoint of overall survival in immunotherapy trials of hepatocellular carcinoma
    Celsa, C.
    Cabibbo, G.
    Enea, M.
    Battaglia, S.
    Rizzo, G. E. M.
    Busacca, A.
    Matranga, D.
    Attanasio, M.
    Reig, M.
    Craxi, A.
    Camma, C.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 : S35 - S35
  • [2] Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
    Cabibbo, Giuseppe
    Celsa, Ciro
    Enea, Marco
    Battaglia, Salvatore
    Rizzo, Giacomo Emanuele Maria
    Busacca, Anita
    Matranga, Domenica
    Attanasio, Massimo
    Reig, Maria
    Craxi, Antonio
    Camma, Calogero
    CANCERS, 2021, 13 (01) : 1 - 14
  • [3] Progression-Free Survival as a Surrogate Endpoint of Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Halabi, Susan
    Rini, Brian
    Escudier, Bernard
    Stadler, Walter M.
    Small, Eric J.
    CANCER, 2014, 120 (01) : 52 - 60
  • [4] Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials
    Mushti, Sirisha L.
    Mulkey, Flora
    Sridhara, Rajeshwari
    CLINICAL CANCER RESEARCH, 2018, 24 (10) : 2268 - 2275
  • [5] Assessment of Progression-free Survival as a Surrogate Endpoint for Overall Survival in Patients With Metastatic Renal Cell Carcinoma
    Negrier, S.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Charbonneau, C.
    Sandin, R.
    Michaelson, M. D.
    Figlin, R. A.
    Motzer, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S163 - S163
  • [6] Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis
    Sjoquist, Katrin M.
    Lord, Sarah J.
    Friedlander, Michael L.
    Simes, Robert John
    Marschner, Ian C.
    Lee, Chee Khoon
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10 : 1 - 16
  • [7] Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
    Wang, Zi-Xian
    Wu, Hao-Xiang
    Xie, Li
    Lin, Wu-Hao
    Liang, Fei
    Li, Jin
    Yang, Zhi-Min
    Xu, Rui-Hua
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (04)
  • [8] Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic colorectal cancer
    Cicero, Giuseppe
    De Luca, Rossella
    Dieli, Francesco
    ONCOTARGETS AND THERAPY, 2018, 11 : 3059 - 3063
  • [9] Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
    Trippa, Lorenzo
    Wen, Patrick Y.
    Parmigiani, Giovanni
    Berry, Donald A.
    Alexander, Brian M.
    NEURO-ONCOLOGY, 2015, 17 (08) : 1106 - 1113
  • [10] META-ANALYSIS OF THE VALIDITY OF PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN METASTATIC COLORECTAL CANCER TRIALS
    Chirila, C.
    Odom, D. M.
    Devercelli, G.
    Khan, S.
    Sherif, B. N.
    Kaye, J. A.
    Molnar, I.
    Sherrill, B. H.
    ANNALS OF ONCOLOGY, 2010, 21 : 202 - 202
12345